In establishing the Hub, FDA gathered feedback from stakeholders through a public meeting, held on Oct. 16, 2024 in collaboration with the Reagan-Udall Foundation.

In collaboration with the Reagan-Udall Foundation for the FDA, we hosted a public meeting, Advancing Rare Disease Therapies Through an FDA Rare Disease Innovation Hub, on October 16, 2024.

Federal agencies recently convened in a pivotal public meeting, hosted by the Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), to discuss emerging treatments for post-traumatic stress disorder (PTSD), with a focus on the potential of psychedelics.